
OTLK
Healthcare · Biotechnology · $100.5M market cap
$0.4130-0.03 (-6.2%)Nov 13, 4:25 PM EST
Next report
Before the open
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · +6.3% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Dec 18, 2026 · upcoming | Before the open | -0.08 | — | — |
| Aug 14, 2026 | Before the open | -0.09 | -0.09 | 0.0% |
| May 15, 2026 | After the close | -0.12 | -0.17 | -41.7% |
| Feb 17, 2026 | Before the open | -0.17 | -0.22 | -29.4% |
| Dec 19, 2025 | Time not confirmed | -0.06 | -0.28 | -366.7% |
| Aug 14, 2025 | After the close | -0.39 | -0.44 | -12.8% |
| May 15, 2025 | After the close | -0.55 | -0.40 | +27.3% |
| Feb 14, 2025 | Before the open | -0.62 | 0.72 | +216.1% |
| Dec 20, 2024 | Before the open | -0.90 | -0.94 | -4.1% |
| Aug 14, 2024 | Before the open | -0.84 | -0.83 | +1.2% |
| May 15, 2024 | After the close | -1.07 | -1.55 | -44.9% |
| Feb 14, 2024 | After the close | -1.07 | -0.78 | +27.1% |
| Dec 22, 2023 | Before the open | -0.06 |
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.…
| -0.05 |
| +16.7% |
| Aug 14, 2023 | After the close | -0.87 | -1.38 | -58.6% |
| May 15, 2023 | After the close | -1.20 | -0.52 | +56.7% |
| Feb 14, 2023 | After the close | -1.30 | -1.59 | -22.3% |
| Dec 29, 2022 | Before the open | -0.07 | -0.06 | +14.3% |
| Aug 10, 2022 | After the close | -1.33 | -1.56 | -17.3% |
| May 13, 2022 | After the close | -1.20 | -1.77 | -47.5% |
| Feb 14, 2022 | Before the open | -0.06 | -0.08 | -33.3% |
| Dec 22, 2021 | After the close | -1.27 | -1.60 | -26.0% |
| Aug 13, 2021 | After the close | -1.40 | -1.40 | 0.0% |
| May 14, 2021 | After the close | -1.80 | -1.80 | 0.0% |
| Feb 16, 2021 | Before the open | -1.65 | -2.20 | -33.3% |
| Dec 23, 2020 | Before the open | -0.08 | -0.13 | -62.5% |
| Aug 14, 2020 | Before the open | -1.90 | -2.20 | -15.8% |
| May 15, 2020 | Before the open | -2.45 | -2.60 | -6.1% |
| Feb 14, 2020 | After the close | -4.40 | -5.60 | -27.3% |
| Dec 19, 2019 | Before the open | -0.31 | -0.12 | +61.3% |
| Aug 14, 2019 | After the close | -7.27 | -4.80 | +34.0% |
| May 15, 2019 | After the close | -13.20 | -19.26 | -45.9% |
| Feb 14, 2019 | After the close | -49.60 | -14.40 | +71.0% |
| Dec 18, 2018 | Before the open | -0.23 | -0.32 | -39.1% |
| Aug 14, 2018 | After the close | -36.80 | -32.00 | +13.0% |
| May 15, 2018 | After the close | -36.80 | -51.20 | -39.1% |
| Feb 14, 2018 | Before the open | -1.92 | -2.48 | -29.2% |